CryoPort Q2 2026: 8% Revenue Rise, First Positive Adjusted EBITDA, 779 Global Clinical Trials
CryoPort Inc. posts Q2 2026 revenue growth, 8 % YoY, and its first positive adjusted EBITDA, signaling a profitable turn toward sustainable growth.
3 minutes to read


